Johnson L - Search Results

1

Exploiting structural principles to design cyclin-dependent kinase inhibitors.

Noble M, Barrett P, Endicott J, Johnson L, McDonnell J, Robertson G, Zawaira A. Noble M, et al. Among authors: johnson l. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):58-64. doi: 10.1016/j.bbapap.2005.08.019. Epub 2005 Sep 12. Biochim Biophys Acta. 2005. PMID: 16361058 Review.

2

Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.

Johnson LN, De Moliner E, Brown NR, Song H, Barford D, Endicott JA, Noble ME. Johnson LN, et al. Pharmacol Ther. 2002 Feb-Mar;93(2-3):113-24. doi: 10.1016/s0163-7258(02)00181-x. Pharmacol Ther. 2002. PMID: 12191604 Review.

3

Structure-based design of cyclin-dependent kinase inhibitors.

Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble ME. Davies TG, et al. Pharmacol Ther. 2002 Feb-Mar;93(2-3):125-33. doi: 10.1016/s0163-7258(02)00182-1. Pharmacol Ther. 2002. PMID: 12191605 Review.

4

Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.

Davies TG, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Wang L, Whitfield HJ. Davies TG, et al. Among authors: johnson ln. Nat Struct Biol. 2002 Oct;9(10):745-9. doi: 10.1038/nsb842. Nat Struct Biol. 2002. PMID: 12244298

5

Protein kinase inhibitors: insights into drug design from structure.

Noble ME, Endicott JA, Johnson LN. Noble ME, et al. Science. 2004 Mar 19;303(5665):1800-5. doi: 10.1126/science.1095920. Science. 2004. PMID: 15031492 Review.

6

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.

Brown NR, Noble ME, Endicott JA, Johnson LN. Brown NR, et al. Among authors: johnson ln. Nat Cell Biol. 1999 Nov;1(7):438-43. doi: 10.1038/15674. Nat Cell Biol. 1999. PMID: 10559988

7

The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition.

Cheng KY, Noble ME, Skamnaki V, Brown NR, Lowe ED, Kontogiannis L, Shen K, Cole PA, Siligardi G, Johnson LN. Cheng KY, et al. Among authors: johnson ln. J Biol Chem. 2006 Aug 11;281(32):23167-79. doi: 10.1074/jbc.M600480200. Epub 2006 May 17. J Biol Chem. 2006. PMID: 16707497 Free article.

8

Halogen bonds form the basis for selective P-TEFb inhibition by DRB.

Baumli S, Endicott JA, Johnson LN. Baumli S, et al. Chem Biol. 2010 Sep 24;17(9):931-6. doi: 10.1016/j.chembiol.2010.07.012. Chem Biol. 2010. PMID: 20851342

9

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

Mesguiche V, Parsons RJ, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury P, Johnson LN, Newell DR, Noble ME, Wang LZ, Hardcastle IR. Mesguiche V, et al. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22. doi: 10.1016/s0960-894x(02)00884-3. Bioorg Med Chem Lett. 2003. PMID: 12482427

10

Mutational analysis supports a structural model for the cell cycle protein kinase p34.

Endicott JA, Nurse P, Johnson LN. Endicott JA, et al. Among authors: johnson ln. Protein Eng. 1994 Feb;7(2):243-53. doi: 10.1093/protein/7.2.243. Protein Eng. 1994. PMID: 8170927

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,885 results

Search Page